| Literature DB >> 25170196 |
Jérôme Dumortier1, Olivier Boillot1, Jean-Yves Scoazec1.
Abstract
Hepatitis C virus (HCV)-related liver disease, including cirrhosis and hepatocellular carcinoma is the main indication for liver transplantation (LT) worldwide. Post-transplant HCV re-infection is almost universal and results in accelerated progression from acute hepatitis to chronic hepatitis, and liver cirrhosis. Comprehension and treatment of recurrent HCV infection after LT have been major issues for all transplant hepatologists and transplant surgeons for the last decades. The aim of this paper is to review the evolution of our knowledge on the natural history of HCV recurrence after LT, including risk factors for disease progression, and antiviral therapy. We will focus our attention on possible ways (present and future) to improve the final long-term results of LT for HCV-related liver disease.Entities:
Keywords: Fibrosis; Hepatitis C; Liver transplantation; Recurrence; Treatment
Mesh:
Substances:
Year: 2014 PMID: 25170196 PMCID: PMC4145750 DOI: 10.3748/wjg.v20.i32.11069
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742